We represented DecisionRx, Inc. in connection with a $100 million equity and debt financing, in collaboration with an institutional investor, to support the launch of a revolutionary pharmaceutical service.
The facility, which was tailored to the unique needs of Decisions Rx’s business model, is expected to fund lab testing and comprehensive medication reviews for over 100,000 patients.
DecisionRx, Inc. is a technology-enabled healthcare services company that optimizes medication therapy for patients.
For more information on this transaction, click here or here.